Related Experiment Video

Updated: Mar 11, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

25.1K

miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression

Senmao Li1, Chenghe Wang2, Xiao Yu1

  • 1Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China.

Oncology Reports
|November 24, 2016
PubMed

Insights

A newly discovered microRNA, miR-3619-5p, shows promise in fighting prostate cancer. Overexpressing this microRNA inhibits cancer cell growth by activating the CDKN1A gene, offering a potential new therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Epigenetics

Background:

  • MicroRNAs (miRNAs) are known to regulate gene expression.
  • RNA activation (RNAa) is a phenomenon where miRNAs can activate gene expression by targeting promoter elements.
  • Prostate cancer is a significant health concern with ongoing research into novel therapeutic targets.

Purpose of the Study:

  • To identify novel miRNAs involved in prostate cancer.
  • To investigate the role of miR-3619-5p in prostate cancer.
  • To explore the potential of miR-3619-5p as a therapeutic agent for prostate cancer.

Main Methods:

  • Identification and quantification of miRNA expression in prostate cancer tissues and cells.
  • Overexpression of miR-3619-5p in prostate cancer cell lines (DU145 and PC3).
  • Analysis of CDKN1A gene expression and its downstream targets using molecular biology techniques.

Main Results:

  • miR-3619-5p was found to be downregulated in prostate cancer tissues and cells.
  • Overexpression of miR-3619-5p activated CDKN1A gene expression by directly targeting its promoter.
  • miR-3619-5p significantly inhibited the growth of DU145 and PC3 prostate cancer cells.
  • miR-3619-5p downregulated key CDKN1A downstream genes, including cyclin D1, CDK4, and CDK6.

Conclusions:

  • miR-3619-5p acts as a tumor suppressor in prostate cancer.
  • The antitumor effects of miR-3619-5p are mediated through the activation of CDKN1A expression.
  • miR-3619-5p represents a potential novel therapeutic target for prostate cancer treatment.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K